Review abstract
Nature Chemical Biology 2, 689 - 700 (2006)
doi:10.1038/nchembio840
There is a Corrigendum (February 2007) associated with this Review.
New approaches to molecular cancer therapeutics
Abstract
Cancer drug development is leading the way in exploiting molecular biological and genetic information to develop 'personalized' medicine. The new paradigm is to develop agents that target the precise molecular pathology driving the progression of individual cancers. Drug developers have benefited from decades of academic cancer research and from investment in genomics, genetics and automation; their success is exemplified by high-profile drugs such as Herceptin (trastuzumab), Gleevec (imatinib), Tarceva (erlotinib) and Avastin (bevacizumab). However, only 5% of cancer drugs entering clinical trials reach marketing approval. Cancer remains a high unmet medical need, and many potential cancer targets remain undrugged. In this review we assess the status of the discovery and development of small-molecule cancer therapeutics. We show how chemical biology approaches offer techniques for interconnecting elements of the traditional linear progression from gene to drug, thereby providing a basis for increasing speed and success in cancer drug discovery.
- Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK.
Correspondence to: Ian Collins1 e-mail: ian.collins@icr.ac.uk
Correspondence to: Paul Workman1 e-mail: paul.workman@icr.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
